Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo therapy for aggressive brain cancer enters final testing phase

NCT ID NCT06419946

Disease control Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether adding lomustine to standard temozolomide chemotherapy improves survival for people with newly diagnosed glioblastoma that has a specific genetic marker (MGMT methylated). About 200 adults aged 18-70 will be randomly assigned to receive either the standard drug alone or the two-drug combination, starting with radiation. Researchers will track survival, tumor progression, side effects, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Temozolomide and lomustine (chemotherapy pills)
What this could lead to
If successful, this combination could extend survival for people with a specific type of glioblastoma, offering a new standard treatment option.
What could go wrong
This is an early-stage Phase 3 trial with only 200 participants. The combination may cause more side effects than standard therapy, and results may not apply to all glioblastoma patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Dec 2033

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed glioblastoma/gliosarcoma, IDH wild type * Methylated MGMT promoter * World Health Organization performance status 0-2 * Age 18-70 Exclusion Criteria: * Previous malignancy within 3 y or malignancy treated non-curatively * Previous chemotherapy or radiotherapy involving the head * Off-protocol tumor-specific treatment * Serious comorbidity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma, IDH-wildtype are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioblastoma, IDH-wildtype MGMT-methylated glioblastoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aarhus University Hospital

    RECRUITING

    Aarhus, Denmark

  • Gävle Hospital

    RECRUITING

    Gävle, Sweden

  • Haukeland University Hospital

    RECRUITING

    Bergen, Norway

  • Kalmar Country Hospital

    RECRUITING

    Kalmar, Sweden

  • Karolinska Institutet

    ENROLLING_BY_INVITATION

    Stockholm, Sweden

  • Kepler University Hospital

    RECRUITING

    Linz, Austria

  • Medizinische Universität Innsbruck

    NOT_YET_RECRUITING

    Innsbruck, Austria

  • Norrlands Universitetssjukhus, Umea, Sweden

    RECRUITING

    Umeå, Sweden

  • Oslo University Hospital

    RECRUITING

    Oslo, Norway

  • Ryhov County Hospital

    RECRUITING

    Jönköping, Sweden

  • Sahlgrenska University Hospital

    RECRUITING

    Gothenburg, Sweden

  • Skåne University Hospital

    NOT_YET_RECRUITING

    Lund, Sweden

  • Sorlandet Sykehus

    RECRUITING

    Kristiansand, Norway

  • St Olavs Hospital

    NOT_YET_RECRUITING

    Trondheim, Norway

  • Stavanger University Hospital

    NOT_YET_RECRUITING

    Stavanger, Norway

  • Sundsvall Hospital

    ENROLLING_BY_INVITATION

    Sundsvall, Sweden

  • University Hospital Graz

    NOT_YET_RECRUITING

    Graz, Austria

  • University Hospital St. Pölten

    ENROLLING_BY_INVITATION

    Sankt Pölten, Austria

  • Uppsala University Hospital

    RECRUITING

    Uppsala, Sweden

  • Örebro University Hospital

    RECRUITING

    Örebro, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.